Alastair was the executive director of Genetic Alliance UK for almost 25 years. In that role he was instrumental in creating an influential and respected voice for patients and families affected by rare and genetic disorders that was able to influence and steer policy, help set the medical research agenda and guide service development by the NHS in ways that incorporate the needs and expectations of the millions of individuals and their families affected by rare genetic conditions, many of which are life limiting, progressive and lead to a reduced life expectancy. Alastair was awarded the OBE for his services to healthcare, and made FRSA for his contribution to the advancement of the understanding of genetics in medicine. Since retiring from his role at Genetic Alliance UK he has continued to work on issues affecting patients and families with rare and genetic disorders, chairing national advisory committees, advising leading pharma and biotech companies and supporting patient organisations in order to promote understanding and improve opportunities for those living with these conditions. Quote on joining: ” I am delighted to have been asked to chair the new Patient Advocacy and Engagement Advisory Board of Congenica, one of the most innovative companies in the genomic diagnostics arena. The Board is a tangible demonstration of the commitment of the company to ensuring that input from patients and families is central to the company’s decision making process, helping to target the real needs of those with life limiting diseases through the creation of opportunities for timely and accurate diagnoses that empower those affected, and those who care for them, to understand and manage their situation better.